TG Therapeutics Inc
TGTXHealthcare|Biotechnology|USA
$57.12
-1.94 (-3.28%)
Tangible Book
$3.81
Graham Number
$15.81
About
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Stock Price
+51.6%(1Y)
Pipeline Summary
54 total trials19
Phase 1
24
Phase 2
10
Phase 3
2
Phase 4
Recruiting: 15Terminated: 18NOT_YET_RECRUITING: 2Completed: 16Active: 3
Active Trials (18)
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
NCT06864936Multiple Sclerosis (MS) - Relapsing-remitting
N/ARecruiting
Enrollment: 30 participants
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT07225361Multiple Sclerosis
Phase 4Recruiting
Enrollment: 40 participants
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
NCT07389590Multiple Sclerosis
Phase 4Recruiting
Enrollment: 50 participants
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
NCT07211633Relapsing Multiple Sclerosis
Phase 3Active
Enrollment: 360 participants
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07673744Myasthenia Gravis
Phase 2Recruiting
Enrollment: 120 participants
BioScore
6.2/10
Watchlist
Ownership
Recent Insider Trades
Echelard YannSELL
2025-11-245,000 shares @ $32.57
Lonial SagarSELL
2025-09-1120,852 shares @ $32.24
Echelard YannSELL
2025-06-1310,000 shares @ $36.94
Power Sean ASELL
2025-01-0621,358 shares @ $29.47
Lonial SagarSELL
2024-11-115,000 shares @ $30.44
Recent News
2026-07-07 15:01:40
2026-07-06 21:00:32
2026-07-06 12:26:45
Data last updated: Jul 12, 2026, 07:30 PM